Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Target Lowered at JPMorgan Chase & Co.

Ascentage Pharma Group International (NASDAQ:AAPG) had its target price reduced by equities research analysts at JPMorgan Chase & Co. from $46.00 to $33.00 in a research note issued on Thursday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of 126.80% from the stock’s current price.

Several other research analysts have also commented on AAPG. BTIG Research reissued a “buy” rating and set a $48.00 price objective on shares of Ascentage Pharma Group International in a report on Friday, August 21st. Raymond James Financial reaffirmed a “buy” rating on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. Finally, B. Riley Financial initiated coverage on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. They issued a “buy” rating and a $45.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating and nine have issued a Buy rating to the company’s stock. According to data from MarketBeat, Ascentage Pharma Group International presently has a consensus rating of “Buy” and an average price target of $44.75.

Ascentage Pharma Group International Stock Down 2.6%

Shares of NASDAQ AAPG traded down $0.39 during mid-day trading on Thursday, hitting $14.55. The company had a trading volume of 11,982 shares, compared to its average volume of 6,862. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.22 and a quick ratio of 1.18. Ascentage Pharma Group International has a 1 year low of $14.46 and a 1 year high of $38.58. The stock’s 50-day moving average price is $16.83 and its 200-day moving average price is $19.41.

Ascentage Pharma Group International (NASDAQ:AAPG) last announced its quarterly earnings results on Wednesday, August 19th. The company reported ($0.65) earnings per share for the quarter. The firm had revenue of $22.24 million during the quarter. On average, sell-side analysts expect that Ascentage Pharma Group International will post -2.42 earnings per share for the current year.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical-stage biopharmaceutical company focused on discovering and developing therapies that target mechanisms involved in programmed cell death. The company’s research is primarily directed toward cancer and other serious diseases in which regulating apoptosis may offer therapeutic benefits.

Its pipeline includes small-molecule drug candidates designed to inhibit proteins that help cancer cells survive. Key programs have included lisaftoclax (APG-2575), a BCL-2 inhibitor being investigated for hematologic malignancies, and APG-115, an MDM2-p53 inhibitor under evaluation in oncology indications.